FINANCE & SPEND
In the rigorous world of pharmaceutical procurement, the definition of value is changing. Where finance and spend traditionally equalled cost-control and supply security, procurement teams today are judged on how a supplier decision affects patient outcomes, system resilience and a product’ s environmental footprint.
Leading that shift is AstraZeneca’ s Ambition Zero Carbon programme. Launched in 2020, the strategy reframes category management: teams no longer buy components in isolation but manage product categories, from active pharmaceutical ingredients to packaging and logistics, through the lens of carbon intensity and supplier transition plans.
Strategic playbooks for decarbonisation That reframing is practical as well as rhetorical. The company reports that the vast majority of its emissions are tied up in Scope 3 sources, AstraZeneca’ s disclosure ranges around the mid-90s percentage depending on the reporting year, so reducing upstream emissions is the decisive lever for meeting corporate net-zero commitments. For procurement, that means shifting from broad mandates to targeted category playbooks that prioritise high-emission inputs such as raw materials, energy-intensive suppliers and transport.
procurementmag. com
105